All News

Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.

In the phase 3 ADAURA trial, 79% of patients who took Tagrisso for three years after lung cancer surgery were alive at eight years, compared with 64% of patients who received a placebo.

Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.

WCLC 2026 brought new lung cancer data on HER2-mutant, PD-L1-positive and EGFR exon 20 insertion-positive non-small cell lung cancer. Here's what patients should know about three key studies.

Twenty-three years after a breast cancer diagnosis at 39, a survivor explains why her garage gym became a place to rebuild strength.

Diagnosed with peritoneal mesothelioma at 21 and given 18 months to live, a survivor reflects on what turning 40 means nearly two decades later.

Lung cancer treatment has changed rapidly since 2021, with new targeted drugs, immunotherapy and treatments designed to overcome resistance.

Most cancers now have at least three or four treatment approaches, and an oncologist explained how cancer heterogeneity shapes the way patients respond.

More than three years after cancer centers first sounded the alarm on chemotherapy shortages, the problem still hasn't gone away.

Learn how to support a friend with cancer by showing up, listening, staying connected and treating them like the same person they were before diagnosis.

After 10 years of living with stage 4 ovarian cancer, one survivor shares why she continues to raise awareness each September and urges women to know the signs, make time for gynecologic care and advocate for themselves.

Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.

Medicare will narrow ostomy suppliers to about eight national contracts, and advocate Ellyn Mantell says a poor fit can put patients in the hospital.

Prostate cancer treatment has advanced rapidly in five years. Explore key FDA approvals, improved treatments and what these changes mean for patients.

FDA grants accelerated approval to Hyrnuo (sevabertinib) for certain patients with HER2-mutated, advanced or metastatic non-small cell lung cancer.

The FDA has withdrawn its accelerated approval of Krazati combined with Erbitux for adults with KRAS G12C-mutated colorectal cancer that is locally advanced or has spread to other parts of the body.

Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.

Dr. Andrew Ip answers common lymphoma questions, from diagnosis and treatment options to CAR T-cell therapy, side effects and hope for patients.

Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.

Hargitay shared her thoughts with CURE regarding her father’s journey, her motivation for speaking out now, and the key message she wants to convey to patients today.

A new study found alcohol-attributable cancer deaths in the U.S. rose from 11,361 in 1990 to 23,126 in 2023, with men and older adults most affected.

Cancer survivor Brynn Forlizzi and caregiver Teddy Aaron created Soothe Note, an app designed to help cancer patients and caregivers manage care.

My multiple myeloma nurse case manager sat in on every appointment, helped me appeal an insurance denial and made sure I never felt like just a number.

Dr. Doured Daghistani discusses how childhood cancer treatment, survivorship care and immunotherapy have evolved this Childhood Cancer Awareness Month.

My daughter was 27 when breast cancer forced a decision about her fertility in days, and I keep thinking about the young women who can't afford that choice.

Explore how personalized treatment, immunotherapy, AI and other advances are transforming cancer care, with insights from Dr. Manmeet Ahluwalia.

Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.

Two and a half years into cancer treatment, my nurse Jenny Gnoza still greets me with a smile, steadies my nerves and finds the vein everyone else misses.